| A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (NCT02773030) | Celgene | 2016-10-14 |
| A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma. (NCT04683393) | Manchester University NHS Foundation Trust | 2016-10-03 |
| Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product (NCT02840110) | Cogent Biosciences, Inc. | 2016-10-01 |
| eHealth for the Elderly (NCT04393090) | Cankado GmbH | 2016-10-01 |
| Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma (NCT02605356) | Bayer | 2016-10-01 |
| A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies (NCT02954445) | Southwest Hospital, China | 2016-10-01 |
| A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma (NCT02919670) | Dana-Farber Cancer Institute | 2016-10-01 |
| Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma (NCT02811978) | Janssen Research & Development, LLC | 2016-09-27 |
| Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) (NCT02851056) | H. Lee Moffitt Cancer Center and Research Institute | 2016-09-27 |
| Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy (NCT02852837) | Janssen Research & Development, LLC | 2016-09-26 |
| Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients (NCT02843074) | SCRI Development Innovations, LLC | 2016-09-21 |
| Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma (NCT02902965) | Pharmacyclics Switzerland GmbH | 2016-09-20 |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG (NCT02916979) | Dartmouth-Hitchcock Medical Center | 2016-09-06 |
| Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients (NCT02812706) | Sanofi | 2016-09-05 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma (NCT03196414) | The First Affiliated Hospital of Soochow University | 2016-09-01 |
| Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma (NCT02916420) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2016-09-01 |
| A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation (NCT02918331) | Janssen Pharmaceutical K.K. | 2016-09-01 |
| Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (NCT02909036) | Memorial Sloan Kettering Cancer Center | 2016-09-01 |
| Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma (NCT02874742) | Janssen Research & Development, LLC | 2016-08-29 |
| Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma (NCT03068637) | Carevive Systems, Inc. | 2016-08-23 |
| An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (NCT02726581) | Bristol-Myers Squibb | 2016-08-10 |
| Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma (NCT02897830) | University Hospital, Toulouse | 2016-08-05 |
| A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency (NCT02833610) | Massachusetts General Hospital | 2016-08-01 |
| Role of CX3CR1-expressing Cells in Hematologic Malignancy (NCT02885623) | Saint Vincent's Hospital, Korea | 2016-08-01 |
| A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms (NCT02842229) | Celgene | 2016-07-20 |
| Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (NCT02719613) | Bristol-Myers Squibb | 2016-07-15 |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (NCT02807454) | Celgene | 2016-07-07 |
| Daratumumab in Combination With ATRA (NCT02751255) | Amsterdam UMC, location VUmc | 2016-07-06 |
| High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma (NCT02597062) | Canadian Cancer Trials Group | 2016-07-05 |
| An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants (NCT02761187) | Takeda | 2016-07-01 |
| A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma (NCT02831686) | Memorial Sloan Kettering Cancer Center | 2016-07-01 |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant (NCT02477878) | Bellicum Pharmaceuticals | 2016-07-01 |
| Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (NCT02728102) | National Heart, Lung, and Blood Institute (NHLBI) | 2016-07-01 |
| Multiparametric Imaging in Multiple Myeloma (NCT02646085) | Yingbing Wang | 2016-07-01 |
| A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (NCT02718833) | Massachusetts General Hospital | 2016-06-21 |
| A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) (NCT02720510) | Novartis Pharmaceuticals | 2016-06-14 |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) (NCT02722941) | H. Lee Moffitt Cancer Center and Research Institute | 2016-06-10 |
| Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (NCT02681302) | Hackensack Meridian Health | 2016-06-07 |
| Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple (NCT02976272) | University Hospital, Clermont-Ferrand | 2016-06-07 |
| A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma (NCT02811822) | GlycoMimetics Incorporated | 2016-06-01 |
| Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment (NCT02977494) | Universitätsklinikum Hamburg-Eppendorf | 2016-06-01 |
| CART-19 Post-ASCT for Multiple Myeloma (NCT02794246) | University of Pennsylvania | 2016-06-01 |
| Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool (NCT02791217) | Assuta Medical Center | 2016-06-01 |
| Pembrolizumab (MK-3475) in MM Patients With Residual Disease (NCT02636010) | PETHEMA Foundation | 2016-06-01 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT (NCT02786485) | Bellicum Pharmaceuticals | 2016-05-01 |
| A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma (NCT02756728) | BioInvent International AB | 2016-05-01 |
| Longterm Follow-up of Subjects Treated With bb2121 (NCT02786511) | Celgene | 2016-04-28 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma (NCT02654990) | pharmaand GmbH | 2016-04-27 |
| Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma (NCT02659293) | University of Chicago | 2016-04-26 |
| A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma (NCT02685826) | Celgene | 2016-04-25 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies (NCT02576496) | Mundipharma Research Limited | 2016-04-14 |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols (NCT02682667) | National Cancer Institute (NCI) | 2016-04-11 |
| Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT (NCT02619812) | Mayo Clinic | 2016-04-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) (NCT07154537) | National Taiwan University Hospital | 2016-03-23 |
| An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) (NCT02654132) | Bristol-Myers Squibb | 2016-03-18 |
| Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM]) (NCT02741544) | Celgene | 2016-03-03 |
| Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation (NCT02719821) | University of Wisconsin, Madison | 2016-03-01 |
| Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (NCT02406222) | University of Leeds | 2016-03-01 |
| Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) (NCT02703779) | Siddhartha Ganguly | 2016-03-01 |
| Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma (NCT02692339) | Celgene | 2016-02-25 |
| Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment (NCT03440411) | Fondazione EMN Italy Onlus | 2016-02-18 |
| A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. (NCT02612779) | Bristol-Myers Squibb | 2016-02-09 |
| Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study (NCT02697383) | Memorial Sloan Kettering Cancer Center | 2016-02-01 |
| BiRd vs. Rd as Initial Therapy in Multiple Myeloma (NCT02516696) | Weill Medical College of Cornell University | 2016-02-01 |
| SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma (NCT02661022) | Stemline Therapeutics, Inc. | 2016-01-01 |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma (NCT02655458) | Hearn Jay Cho | 2016-01-01 |
| Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma (NCT02626481) | University Hospital, Lille | 2015-12-28 |
| Study of bb2121 in Multiple Myeloma (NCT02658929) | Celgene | 2015-12-22 |
| Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma (NCT02628704) | Karyopharm Therapeutics Inc | 2015-12-01 |
| UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination (NCT02578121) | University of Arkansas | 2015-12-01 |
| Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (NCT02461888) | University of Leeds | 2015-12-01 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (NCT02441686) | Dana-Farber Cancer Institute | 2015-12-01 |
| Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma (NCT02447055) | Washington University School of Medicine | 2015-12-01 |
| Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients (NCT03406091) | Fondazione EMN Italy Onlus | 2015-11-26 |
| Multiple Myeloma Minimal Residual Disease (NCT02627261) | Hospices Civils de Lyon | 2015-11-23 |
| A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (NCT02561962) | Amgen | 2015-11-20 |
| A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma (NCT02609230) | Fox Chase Cancer Center | 2015-11-05 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant (NCT02589860) | Sherif S. Farag | 2015-10-30 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (NCT02519452) | Janssen Research & Development, LLC | 2015-10-22 |
| Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) (NCT02579863) | Merck Sharp & Dohme LLC | 2015-10-19 |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) (NCT02576977) | Merck Sharp & Dohme LLC | 2015-10-19 |
| Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients (NCT02426723) | JW Pharmaceutical | 2015-10-19 |
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT02477215) | Parameswaran Hari | 2015-10-09 |
| STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS (NCT02586038) | Mario Boccadoro | 2015-10-01 |
| URMC Related Haplo-identical Donor BMT (NCT02660281) | University of Rochester | 2015-10-01 |
| PDD vs PAD to Treat Initially Diagnosed MM (NCT02577783) | The First Affiliated Hospital of Soochow University | 2015-10-01 |
| Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers (NCT02682953) | University of Maryland, Baltimore | 2015-10-01 |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients (NCT02343042) | Karyopharm Therapeutics Inc | 2015-10-01 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159) | National Cancer Institute (NCI) | 2015-09-24 |
| Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (NCT02412878) | Amgen | 2015-09-09 |
| CART-BCMA Cells for Multiple Myeloma (NCT02546167) | University of Pennsylvania | 2015-09-03 |
| Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients (NCT02384083) | PETHEMA Foundation | 2015-09-01 |
| Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies (NCT02507479) | Sheba Medical Center | 2015-09-01 |
| Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (NCT02566265) | Yale University | 2015-09-01 |
| A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (NCT02541383) | Intergroupe Francophone du Myelome | 2015-09-01 |